AKAR, S. Et Al. 2018. The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients. Annual European Congress of Rheumatology , (Amsterdam, Netherlands), 1012.

AKAR, S., KİRAZ, S., GERÇİK, Ö., ERTENLİ, A. İ., KÜÇÜKŞAHİN, O., DALKILIÇ, H. E., ... BES, C.(2018). The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients . Annual European Congress of Rheumatology (pp.1012). Amsterdam, Netherlands

AKAR, SERVET Et Al. "The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients," Annual European Congress of Rheumatology, Amsterdam, Netherlands, 2018

AKAR, SERVET Et Al. "The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients." Annual European Congress of Rheumatology , Amsterdam, Netherlands, pp.1012, 2018

AKAR, S. Et Al. (2018) . "The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients." Annual European Congress of Rheumatology , Amsterdam, Netherlands, p.1012.

@conferencepaper{conferencepaper, author={SERVET AKAR Et Al. }, title={The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients}, congress name={Annual European Congress of Rheumatology}, city={Amsterdam}, country={Netherlands}, year={2018}, pages={1012} }